We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 554

Patents Court upholds supplementary protection certificate for a novel enantiomer in Generics UK Limited v Daiichi

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • December 31 2008

Generics (UK) Limited (“GUK”) was unsuccessful in its attempt before the Patents Court (Mr Justice Kitchin) to revoke Daiichi's Supplementary Protection Certificate (“SPC”) in respect of levofloxacin

Europe rules against embryonic stem cells patent

  • Wragge & Co LLP
  • -
  • European Union
  • -
  • January 7 2009

By a landmark decision dated 25 November 2008, the Enlarged Board of Appeal of the European Patent Office (EPO) refused a patent application by Wisconsin Alumni Research Foundation (WARF) (the Appellant) covering the use of human embryonic stem cells (ESCs

EPO Enlarged Board of Appeal rejects patent that requires human embryos for implementation

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • December 31 2008

In its decision of 25 November 2008 the EPO Enlarged Board of Appeal (EBA) considered four questions referred to it by the EPO Technical Board of Appeal concerning a patent application by Wisconsin Alumni Research Foundation (WARF) with claims to “a cell culture comprising primate embryonic stem cells…”

Federal Circuit affirms award of attorneys’ fees for litigation misconduct

  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • -
  • USA
  • -
  • April 28 2009

In ICU Medical, Inc. v. Alaris Medical Systems, Inc., No. 08-1077 (Fed. Cir. Mar. 13, 2009), the Federal Circuit held that the district court correctly granted SJ of noninfringement and SJ of invalidity, did not commit clear error in awarding attorneys fees, and did not abuse its discretion in granting Rule 11 sanctionsall in favor of Alaris Medical Systems, Inc. (“Alaris”

Lundbeck v. Cobalt and Ratiopharm

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 19 2009

Lundbeck brought a judicial review of the Minister's decision to accept the generic companies' ANDSs for their brand of memantine

AB Hassle v. Apotex

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 28 2008

The generic company brought a motion asking the Court to reconsider its decision in two proceedings where prohibition was granted and affirmed by the Federal Court of Appeal

Life sciences patent litigation a summary of calendar year 2007

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • February 28 2008

2007 saw slightly fewer fully contested first instance hearings in the life sciences sector in the English Patents Court on which judgment was given, than the previous year (on which we reported in March 2007

Does requesting and receiving approval for a pharmaceutical create a threat of patent infringement? A German perspective

  • Bird & Bird
  • -
  • Germany
  • -
  • February 28 2008

Under German law, neither the application for a marketing approval nor obtaining it constitutes a ‘use’ act under Section 9 German Patent Act

The Court of Appeal overturns Eli Lilly’s interim injunction

  • McDermott Will & Emery
  • -
  • United Kingdom
  • -
  • February 28 2008

In Eli Lilly & Company and Lilly Icos LLC v 8PM Chemists Ltd, 2008 EWCA Civ 24, the Court of Appeal discharged an interim injunction, previously granted by the High Court, on the basis that the Claimants did not have an arguable case of trade mark infringement

District court denies all challenges to FDA decision concerning rights to market and sell generic versions of Pfizer’s Norvasc

  • McDermott Will & Emery
  • -
  • USA
  • -
  • May 30 2007

In a case involving generic versions of Pfizer’s high blood pressure drug Norvasc (amlodipine besylate) and the availability and applicability of both 180-day generic drug exclusivity and pediatric exclusivity the United States District Court for the District of Columbia denied all requests for preliminary injunction related to amlodipine besylate tablets and supported the U.S. Food and Drug Administration’s (FDA) position concerning Mylan’s current status as holder of the only approved Abbreviated New Drug Application (ANDA) for all strengths of this product

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy